These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 8944328

  • 21. p53 mutations and expression in breast carcinoma in situ.
    Lukas J, Niu N, Press MF.
    Am J Pathol; 2000 Jan; 156(1):183-91. PubMed ID: 10623666
    [Abstract] [Full Text] [Related]

  • 22. Protein expression of c-erbB-2 and p53 in normal ducts, ductal carcinoma in situ and invasive carcinoma of the same breast.
    Menezes MV, Cestari AL, Almeida O, Alvarenga M, Pinto GA, Gurgel MS, Souza GA, Zeferino LC.
    Sao Paulo Med J; 2006 May 04; 124(3):121-4. PubMed ID: 17119686
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. p63 expression in normal, hyperplastic and malignant breast tissues.
    Wang X, Mori I, Tang W, Nakamura M, Nakamura Y, Sato M, Sakurai T, Kakudo K.
    Breast Cancer; 2002 May 04; 9(3):216-9. PubMed ID: 12185332
    [Abstract] [Full Text] [Related]

  • 27. Evaluation of numerical abnormalities of chromosomes 1 and 17 in proliferative epithelial breast lesions using fluorescence in situ hybridization.
    Marinho AF, Botelho M, Schmitt FC.
    Pathol Res Pract; 2000 May 04; 196(4):227-33. PubMed ID: 10782466
    [Abstract] [Full Text] [Related]

  • 28. Carcinoma in situ of the breast: correlation of histopathology to immunohistochemical markers and DNA ploidy.
    Ottesen GL, Christensen IJ, Larsen JK, Larsen J, Baldetorp B, Linden T, Hansen B, Andersen J.
    Breast Cancer Res Treat; 2000 Apr 04; 60(3):219-26. PubMed ID: 10930109
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Down-regulation of gelsolin expression in human breast ductal carcinoma in situ with and without invasion.
    Asch HL, Winston JS, Edge SB, Stomper PC, Asch BB.
    Breast Cancer Res Treat; 1999 May 04; 55(2):179-88. PubMed ID: 10481945
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Recent advances in studies on in-situ and invasive ductal carcinoma].
    Zhang RJ, Niu Y, Gao YX.
    Zhonghua Bing Li Xue Za Zhi; 2009 Jan 04; 38(1):63-5. PubMed ID: 19489232
    [No Abstract] [Full Text] [Related]

  • 34. Characterization of extensive genetic alterations in ductal carcinoma in situ by fluorescence in situ hybridization and molecular analysis.
    Murphy DS, Hoare SF, Going JJ, Mallon EE, George WD, Kaye SB, Brown R, Black DM, Keith WN.
    J Natl Cancer Inst; 1995 Nov 15; 87(22):1694-704. PubMed ID: 7473818
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Expression and significance of hTERT mRNA in breast carcinoma and its relation to p53].
    Tang F, Gu DH, Wang H, Zhu TF, Zhu HG, Xu ZD, Hu XQ.
    Zhonghua Zhong Liu Za Zhi; 2006 Mar 15; 28(3):192-5. PubMed ID: 16875603
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Amplification of the MDM2 gene in human breast cancer and its association with MDM2 and p53 protein status.
    McCann AH, Kirley A, Carney DN, Corbally N, Magee HM, Keating G, Dervan PA.
    Br J Cancer; 1995 May 15; 71(5):981-5. PubMed ID: 7734324
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.